1.Donor Surgical Morbidity in Pediatric Living-Donor Liver Transplant: A Portuguese Experience
José Pedro Fernandes dos SANTOS ; Ricardo MARTINS ; Maria Francelina LOPES
Pediatric Gastroenterology, Hepatology & Nutrition 2021;24(6):528-534
Purpose:
Living-donor liver transplant emerged as an alternative treatment for end stage liver disease due to the lack of cadaveric organs availability that met the demand. In Portugal, pediatric living-donor liver transplant (P-LDLT) was initiated in 2001 in Portugal in order to compensate for the scarcity of cadaveric organs for such cases. The aim of this study was to retrospectively analyze the morbi-mortality of the 28 donors included in P-LDLT program performed at Coimbra's Pediatric Hospital (CHUC), a Portuguese reference center.
Methods:
We retrospectively collected pertinent donor data and stratified complications according to Clavien's scoring system.
Results:
In total, 28.6% (n=8) of the donors had surgical complications. According to Clavien-Dindo's classification, two donors had major complications (Clavien grade ≥3), four donors had grade 2 complications, and two donors had grade 1 complications. There were no P-LDLT-related mortalities in the present case series. The most common verified complications were biliary tract injuries and superficial incisional infections, which are consistent with the complications reported in worldwide series.
Conclusion
These patients from CHUC shows that donor hepatectomy in P-LDLT is a safe procedure, with low morbidity and without mortality.
2.Absence of Longer Reorientation Times in Patients Undergoing Electroconvulsive Therapy and Concomitant Treatment with Lithium
Ricardo MARTINS-ASCENCAO ; Nuno RODRIGUES-SILVA ; Nuno TROVÃO
Clinical Psychopharmacology and Neuroscience 2021;19(4):695-704
Objective:
Lithium is a drug of choice in the treatment of bipolar disorder and refractory depressive disorders. However, previous research suggests lithium has a negative cognitive impact in recovery from electroconvulsive therapy (ECT) and a higher risk of delirium, so patients are often required to stop taking lithium before ECT, despite risk of relapse.We studied the cognitive impact of serum lithium levels in patients undergoing ECT.
Methods:
This was an observational prospective study. Serum lithium levels, thyroid and biochemical parameters were measured prior to each ECT session. Time elapsed from the anesthetic induction to the electrical stimulus and then to the patients’ reorientation was recorded, as well as the motor seizure duration and electroencephalogram (EEG) seizure duration. A statistical analysis using a linear mixed model was run while adjusting for confounding factors.
Results:
Ten participants underwent a total of 86 ECT sessions (41% right unilateral ultrabrief pulse, and 59% bilateral brief pulse). A negative interaction between lithium levels and reorientation time was found among those doing bilateral brief pulse ECT. No association was observed in patients doing unilateral ultrabrief pulse ECT. No significant relationship was observed between lithium and both motor and EEG-assessed seizure duration.
Conclusion
This study suggests that low to moderate serum lithium levels (< 0.7 mmol/L) might have no harmful cognitive effects in patients under right unilateral ultrabrief pulse and bilateral brief pulse ECT.
3.Hepatocellular carcinoma associated with progressive intrahepatic familial cholestasis type 2: a case report
João Miguel PIMENTEL ; Susana NOBRE ; Rui Caetano OLIVEIRA ; Ricardo MARTINS ; Maria Augusta CIPRIANO
Clinical Transplantation and Research 2024;38(3):241-245
Progressive familial intrahepatic cholestasis type 2 (PFIC2) is an autosomal recessive disorder typically presenting in infancy with cholestasis and rapidly progressing to cirrhosis. PFIC has been associated with an elevated risk of hepatocellular carcinoma (HCC), a neoplasm that is uncommon in children. PFIC type 4 has the strongest link to this type of cancer, although a few cases have also been connected to PFIC2. Herein, we report the case of a 2-year-old boy who underwent liver transplantation due to PFIC2. Histological examination showed cirrhosis and four small HCCs. Over a 20-year period following the transplantation, there was no recurrence of the disease or HCC. Although rare, HCC development can occur in PFIC and may complicate the prognosis. Liver transplantation offers a potential cure for both the metabolic disease and the neoplasm.
4.Hepatocellular carcinoma associated with progressive intrahepatic familial cholestasis type 2: a case report
João Miguel PIMENTEL ; Susana NOBRE ; Rui Caetano OLIVEIRA ; Ricardo MARTINS ; Maria Augusta CIPRIANO
Clinical Transplantation and Research 2024;38(3):241-245
Progressive familial intrahepatic cholestasis type 2 (PFIC2) is an autosomal recessive disorder typically presenting in infancy with cholestasis and rapidly progressing to cirrhosis. PFIC has been associated with an elevated risk of hepatocellular carcinoma (HCC), a neoplasm that is uncommon in children. PFIC type 4 has the strongest link to this type of cancer, although a few cases have also been connected to PFIC2. Herein, we report the case of a 2-year-old boy who underwent liver transplantation due to PFIC2. Histological examination showed cirrhosis and four small HCCs. Over a 20-year period following the transplantation, there was no recurrence of the disease or HCC. Although rare, HCC development can occur in PFIC and may complicate the prognosis. Liver transplantation offers a potential cure for both the metabolic disease and the neoplasm.
5.Hepatocellular carcinoma associated with progressive intrahepatic familial cholestasis type 2: a case report
João Miguel PIMENTEL ; Susana NOBRE ; Rui Caetano OLIVEIRA ; Ricardo MARTINS ; Maria Augusta CIPRIANO
Clinical Transplantation and Research 2024;38(3):241-245
Progressive familial intrahepatic cholestasis type 2 (PFIC2) is an autosomal recessive disorder typically presenting in infancy with cholestasis and rapidly progressing to cirrhosis. PFIC has been associated with an elevated risk of hepatocellular carcinoma (HCC), a neoplasm that is uncommon in children. PFIC type 4 has the strongest link to this type of cancer, although a few cases have also been connected to PFIC2. Herein, we report the case of a 2-year-old boy who underwent liver transplantation due to PFIC2. Histological examination showed cirrhosis and four small HCCs. Over a 20-year period following the transplantation, there was no recurrence of the disease or HCC. Although rare, HCC development can occur in PFIC and may complicate the prognosis. Liver transplantation offers a potential cure for both the metabolic disease and the neoplasm.
6.Hepatocellular carcinoma associated with progressive intrahepatic familial cholestasis type 2: a case report
João Miguel PIMENTEL ; Susana NOBRE ; Rui Caetano OLIVEIRA ; Ricardo MARTINS ; Maria Augusta CIPRIANO
Clinical Transplantation and Research 2024;38(3):241-245
Progressive familial intrahepatic cholestasis type 2 (PFIC2) is an autosomal recessive disorder typically presenting in infancy with cholestasis and rapidly progressing to cirrhosis. PFIC has been associated with an elevated risk of hepatocellular carcinoma (HCC), a neoplasm that is uncommon in children. PFIC type 4 has the strongest link to this type of cancer, although a few cases have also been connected to PFIC2. Herein, we report the case of a 2-year-old boy who underwent liver transplantation due to PFIC2. Histological examination showed cirrhosis and four small HCCs. Over a 20-year period following the transplantation, there was no recurrence of the disease or HCC. Although rare, HCC development can occur in PFIC and may complicate the prognosis. Liver transplantation offers a potential cure for both the metabolic disease and the neoplasm.
8.Serum level changes of long chain-polyunsaturated fatty acids in patients undergoing periodontal therapy combined with one year of omega-3 supplementation: a pilot randomized clinical trial.
Gisele Lago MARTINEZ ; Josely Correa KOURY ; Marcela Anjos MARTINS ; Fernanda NOGUEIRA ; Ricardo Guimaraes FISCHER ; Anders GUSTAFSSON ; Carlos Marcelo S FIGUEREDO
Journal of Periodontal & Implant Science 2014;44(4):169-177
PURPOSE: We aimed to investigate the impact of nonsurgical periodontal treatment combined with one-year dietary supplementation with omega (omega)-3 on the serum levels of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA), and arachidonic acid (AA). METHODS: Fifteen patients with chronic generalized periodontitis were treated with scaling and root planing. The test group consisted of seven patients (43.1+/-6.0 years) supplemented with omega-3, consisting of EPA plus DHA, three capsules, each of 300 mg of omega-3 (180-mg EPA/120-mg DHA), for 12 months. The control group was composed of eight patients (46.1+/-11.6 years) that took a placebo capsule for 12 months. The periodontal examination and the serum levels of DPA, EPA, DHA, and AA were performed at baseline (T0), and 4 (T1), and 12 (T2) months after therapy. RESULTS: In the test group, AA and DPA levels had been reduced significantly at T1 (P<0.05). AA and EPA levels had been increased significantly at T2 (P<0.05). The DeltaEPA was significantly higher in the test compared to the placebo group at T2-T0 (P=0.02). The AA/EPA had decreased significantly at T1 and T2 relative to baseline (P<0.05). CONCLUSIONS: Nonsurgical periodontal treatment combined with omega-3 supplementation significantly increased the EPA levels and decreased the AA/EPA ratio in serum after one year follow-up. However, no effect on the clinical outcome of periodontal therapy was observed.
Arachidonic Acid
;
Capsules
;
Dietary Supplements
;
Eicosapentaenoic Acid
;
Fatty Acids*
;
Follow-Up Studies
;
Humans
;
Periodontitis
;
Root Planing
9.Miller Fisher Syndrome in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection:A Systematic Review
Paulo Ricardo MARTINS-FILHO ; Ana Luiza Pereira DE ANDRADE ; Ana Júlia Pereira DE ANDRADE ; Maria Daniella MOURA DA SILVA ; Adriano Antunes de SOUZA ARAÚJO ; Paula Santos NUNES ; Victor Santana SANTOS ; Lis Campos FERREIRA ; Eduardo Luis de AQUINO NEVES ; Lucindo José QUINTANS-JÚNIOR
Journal of Clinical Neurology 2021;17(4):541-545
Background:
and PurposeMiller Fisher syndrome (MFS) is a subtype of Guillain-Barré syndrome characterized by the triad of ophthalmoparesis, areflexia, and ataxia. Although cases of MFS have been associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, no studies have synthesized the clinical characteristics of patients with this condition.
Methods:
In this rapid systematic review, we searched the PubMed database to identify studies on MFS associated with SARS-CoV-2 infection.
Results:
This review identified 11 cases, of whom 3 were hospitalized with motor and/or sensory polyneuropathy as the first sign of SARS-CoV-2 infection. SARS-CoV-2 RNA was not detected in analyses of cerebrospinal fluid, suggesting a mechanism of immune-mediated injury rather than direct viral neurotropism. However, antiganglioside antibodies were found in only two of the nine patients tested. It is possible that target antigens other than gangliosides are involved in MFS associated with SARS-CoV-2 infection.
Conclusions
The present patients exhibited clinical improvement after being treated with intravenous immunoglobulin. Although rare, patients with SARS-CoV-2 infection may present neurological symptoms suggestive of MFS. Early recognition of the MFS clinical triad is essential for the timely initiation of treatment.
10.Miller Fisher Syndrome in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection:A Systematic Review
Paulo Ricardo MARTINS-FILHO ; Ana Luiza Pereira DE ANDRADE ; Ana Júlia Pereira DE ANDRADE ; Maria Daniella MOURA DA SILVA ; Adriano Antunes de SOUZA ARAÚJO ; Paula Santos NUNES ; Victor Santana SANTOS ; Lis Campos FERREIRA ; Eduardo Luis de AQUINO NEVES ; Lucindo José QUINTANS-JÚNIOR
Journal of Clinical Neurology 2021;17(4):541-545
Background:
and PurposeMiller Fisher syndrome (MFS) is a subtype of Guillain-Barré syndrome characterized by the triad of ophthalmoparesis, areflexia, and ataxia. Although cases of MFS have been associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, no studies have synthesized the clinical characteristics of patients with this condition.
Methods:
In this rapid systematic review, we searched the PubMed database to identify studies on MFS associated with SARS-CoV-2 infection.
Results:
This review identified 11 cases, of whom 3 were hospitalized with motor and/or sensory polyneuropathy as the first sign of SARS-CoV-2 infection. SARS-CoV-2 RNA was not detected in analyses of cerebrospinal fluid, suggesting a mechanism of immune-mediated injury rather than direct viral neurotropism. However, antiganglioside antibodies were found in only two of the nine patients tested. It is possible that target antigens other than gangliosides are involved in MFS associated with SARS-CoV-2 infection.
Conclusions
The present patients exhibited clinical improvement after being treated with intravenous immunoglobulin. Although rare, patients with SARS-CoV-2 infection may present neurological symptoms suggestive of MFS. Early recognition of the MFS clinical triad is essential for the timely initiation of treatment.